Report Sections

See All Reports

  • HP:0004808: Acute myeloid leukemia
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0004808: Acute myeloid leukemia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (2)

    Name (Synonyms) Correlation
    drug1598 IO-202 Dose Escalation Wiki 0.71
    drug1599 IO-202 Dose Expansion Wiki 0.71

    Correlated MeSH Terms (6)

    Name (Synonyms) Correlation
    D015470 Leukemia, Myeloid, Acute NIH 1.00
    D007951 Leukemia, Myeloid, NIH 0.71
    D015479 Leukemia, Myelomonocytic, Acute NIH 0.71
    Name (Synonyms) Correlation
    D015477 Leukemia, Myelomonocytic, Chronic NIH 0.71
    D007938 Leukemia, NIH 0.63
    D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma NIH 0.41

    Correlated HPO Terms (3)

    Name (Synonyms) Correlation
    HP:0012324 Myeloid leukemia HPO 0.71
    HP:0012325 Chronic myelomonocytic leukemia HPO 0.71
    HP:0001909 Leukemia HPO 0.41

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials

    1 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered IO-202 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

    To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy.

    1. AML M5
    2. AML M4
    3. AML, Nos
    4. Acute Myelogenous Leukemia in Relapse
    5. Myelomonocytic Leukemia, Chronic
    1. Drug: IO-202 Dose Escalation
    2. Drug: IO-202 Dose Expansion
    MeSH:Leukemia Leukemia, Myeloid Leukemia, Myelomonocytic, Acute Leukemia, Myelomonocytic, Chronic Leukemia, Myeloid, Acute
    HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Acute myelomonocytic leukemia Chronic myelomonocytic leukemia Leukemia Myeloid leukemia

    Primary Outcomes

    Description: Incidence of adverse events

    Measure: Safety of IO-202 as measured by incidence of adverse events.

    Time: From first dose of IO-202 to 30 days following last study treatment

    Description: Severity of adverse events

    Measure: Safety of IO-202 as measured by severity of adverse events.

    Time: From first dose of IO-202 to 30 days following last study treatment

    Description: Incidence dose interruptions and dose reductions

    Measure: Tolerability of IO-202 as measured by incidence and duration of dose interruptions and dose reductions of study treatment

    Time: From first dose of IO-202 to 30 days following last study treatment

    Secondary Outcomes

    Description: Maximum concentration (Cmax) of IO-202

    Measure: To characterize the pharmacokinetics (PK) of IO-202 as defined by maximum plasma concentration (Cmax)

    Time: Through study completion, an average of 1 year

    Description: measure area under the curve (AUC) of IO-202

    Measure: To characterize the PK of IO-202 as defined by area under the curve (AUC)

    Time: Through study completion, an average of 1 year

    Description: Measure anti-drug antibodies in plasma.

    Measure: To evaluate the incidence of anti-drug antibodies against IO-202

    Time: Through study completion, an average of 1 year

    Description: Measure response rates in patients with anti-drug antibodies.

    Measure: To measure rates of response to IO-202 in patients with anti-drug antibodies

    Time: Through study completion, an average of 1 year

    Other Outcomes

    Description: Statistical correlation levels of target expression on leukemic blasts with response rate

    Measure: To correlate target expression with response rates

    Time: Through study completion, a average of 1 year

    Description: Statistical correlation of target expression on leukemic blasts with adverse event rates

    Measure: To correlate target expression with rates of adverse events

    Time: Through study completion, a average of 1 year

    Description: Measure immunophenotype of leukemic blasts from bone marrow aspirates after study treatment

    Measure: To evaluate immunophenotype of leukemic blasts after study treatment.

    Time: Through study completion, a average of 1 year
    2 National Retrospective Monitoring of Patients With Acute Leukemia Infected by COronaVirus Disease 2019 (COVID-19)

    The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia. The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.

    1. Acute Myeloblastic Leukemia
    2. Acute Lymphoblastic Leukemia
    3. SARS-CoV-2
    MeSH:Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid, Acute
    HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Leukemia

    Primary Outcomes

    Description: Factors associated with overall survival will be analyzed : center, sex, leukemia subtype, previous treatment by corticosteroids, and comorbidities (respiratory, renal, cardiac, weight, diabetes)

    Measure: Clinical prognostic factors for infection with COVID-19

    Time: Day 0

    Description: neutrophils and lymphocytes count at the time of SARS-COV2 infection

    Measure: Biological prognostic factors for infection with COVID-19

    Time: Day 0

    Description: Describe the management carried out concerning coronavirus infection and its impact of the treatment of acute leukemia (non-invasive ventilation, orotracheal intubation, vasopressor requiring, treatments used, cause of death

    Measure: Medical care of Coronavirus infection

    Time: within 12 months after diagnosis

    HPO Nodes


    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,180 reports on interventions/drugs


    691 reports on MeSH terms


    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook